Project description
Pioneering a paradigm shift in cancer therapy through innovative catalysis
As cancer continues to challenge medical boundaries, the quest for more effective and less invasive treatments intensifies. Traditional therapies often fall short, prompting a search for novel solutions. With the support of Marie Skłodowska-Curie Actions, the Co-CaReD project aims to reshape cancer treatment by harnessing the power of in-cell redox catalysis. By designing cutting-edge catalytic systems based on cost-effective and biocompatible cobalt, Co-CaReD aims to create a new frontier of therapies, offering hope for safer and more accessible options in the fight against cancer. Unlike its counterparts, cobalt boasts unique chemical properties that pave the way for unparalleled reactivity pathways and drug candidates that are more affordable and less toxic.
Objective
The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more efficient, safer, and less invasive medicines.
Co-CaReD aims to design new in-cell catalytic systems based on half-sandwich Co(III) complexes. Cobalt combines effective catalytic performances for biomedical applications and high catalytic versatility. Moreover, it is a cheap, sustainable, and biocompatible metal whose peculiar chemical properties can access unique reactivity pathways. The project will focus on the development of new synthetic catalysts, on their applications in redox reactions of therapeutic interest, involving known examples and unprecedent cases of study, and on the unveiling of their biological mechanism of action in cancer cells.
Co-CaReD will be implemented in a vibrant and stimulating research environment at IMDEA Nanociencia, in Dr. Ana Pizarro research group. The project will benefit of the complementary expertise of the ER in organometallic chemistry and redox catalysis and of the supervisor in studying the intracellular reactivity at the molecular level of metal-based drugs. An intense training plan is designed to equip the researcher with the necessary skills to study the biological activity of the Co(III) catalysts including single-cell studies and to design proof-of-concept experiments that confirm the occurrence of a metal-based catalytic reactivity inside the human cells.
The main goal of Co-CaReD is to generate novel redox catalytic systems based on more biocompatible, less toxic, and cheaper cobalt drug candidates, as complementary tools to noble metal complexes.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural scienceschemical sciencesinorganic chemistrytransition metals
- medical and health sciencesclinical medicineoncology
- natural scienceschemical sciencescatalysis
You need to log in or register to use this function
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European FellowshipsCoordinator
28049 Madrid
Spain